Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31209543 | 0.86 | OPRK1 (0.33) | PIK3CDALDH1A1OPRK1HSD17B10SMN1; SMN2 | |
| SCHEMBL31209540 | 0.86 | CCR5 (0.33) | PIK3CDOPRK1HSD17B10SMN1; SMN2 | |
| SCHEMBL31209595 | 0.85 | HSD11B1 (0.36) | HSD11B1OPRK1HSD17B10 | |
| SCHEMBL31209942 | 0.85 | PRMT5 (0.33) | ALDH1A1OPRK1HSD17B10 | |
| SCHEMBL31085807 | 0.85 | HSD17B10 (0.36) | OPRK1HSD17B10SMN1; SMN2HPGDCHRM2 | |
| SCHEMBL31085624 | 0.85 | HSD17B10 (0.36) | OPRK1HSD17B10SMN1; SMN2HPGDCHRM2 | |
| SCHEMBL31208605 | 0.85 | HSD17B10 (0.36) | OPRK1HSD17B10SMN1; SMN2HPGDCHRM2 | |
| SCHEMBL31085636 | 0.85 | HSD17B10 (0.36) | OPRK1HSD17B10SMN1; SMN2HPGDCHRM2 | |
| SCHEMBL33525545 | 0.84 | HPGD (0.43) | OPRK1HSD17B10SMN1; SMN2HPGDCHRM2 | |
| SCHEMBL33525876 | 0.84 | HSD17B10 (0.41) | OPRK1HSD17B10SMN1; SMN2HPGDCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368193-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368193-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | PIK3CD 588/4885HSD11B1 2013/4885ALDH1A1 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.